Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Golden-ADC

Financiado

Cerrado

An Insulin-Gold Nanoplatform as Enhanced Antibody-Drug Conjugate Cancer Therapy

Antibody-drug conjugates (ADCs) have emerged as promising therapies by combining the precision targeting abilities of antibodies with the potency of chemotherapy drugs, to directly attack cancer cells and minimize damage to health... ver más

31/08/2025

BIU

Presupuesto desconocido

Líder del proyecto

BAR ILAN UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-01

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

BIU

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-105416RB-I00 GRANULOS DE SECRECION ARTIFICIALES PARA LA ENTREGA REMOTA DE... 145K€ Cerrado

MultiTheranostic Theranostic magnetic nano-based codelivery system for boosti... Cerrado

Meta-Targeting Macro Nanomedicine to Treat Metastatic Cancer 2M€ Cerrado

PID2020-118448RB-C22 DESARROLLO DE NANOSISTEMAS MULTIFUNCIONALES BASADOS EN METAL... 121K€ Cerrado

THERMONANO Nanoassemblies for the subcutaneous self administration of a... 2M€ Cerrado

DINAMIT Dual Imaging Nano Micro sized Theranostics against cancer 265K€ Cerrado

Duración del proyecto: 17 meses Fecha Inicio: 2024-03-01
Fecha Fin: 2025-08-31

Líder del proyecto

BAR ILAN UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Antibody-drug conjugates (ADCs) have emerged as promising therapies by combining the precision targeting abilities of antibodies with the potency of chemotherapy drugs, to directly attack cancer cells and minimize damage to healthy tissue. However, approved ADCs show low efficacies in treating solid tumours, due to inherent challenges. These include design challenges, which limit the drug-antibody ratio and the ability to integrate multiple drug types, and delivery challenges, in which pharmacokinetics and tumor barriers limit ADC accumulation and distribution within tumours. In the framework of the ERC-CoG project, we are developing gold nanoparticles (GNPs) that harness insulin for delivery of large therapeutics, including antibodies, across biological barriers. As part of this research, we have recently revealed that these insulin-GNPs can be further developed as an ADC nanoplatform. This Golden-ADC nanoplatform enables simple conjugation of large payloads of multiple antibodies and drug types, shows efficacy in cancer cell models, and enhances in vivo tumor accumulation, together with deep penetration and wide distribution throughout the tumour. In this PoC proposal, we will test our Golden-ADC nanoplatform for effective and safe treatment of triple negative breast cancer, due to the potential high benefits that our nanoplatform can provide for this hard-to-treat cancer, which has a long-standing paucity of effective therapies. Within GOLDEN ADC, we aim to acheive significant progress in the technology development process, by proof of concept demonstration of efficacy and safety of the Golden-ADC conjugated with multiple drugs in in-vivo triple negative breast cancer models. We also intend to achieve business readiness, via consolidating the IP strategy, undertaking a comprehensive market analysis, end-user engagement and developing the business strategy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores